Table 1. Ongoing clinical trials evaluating PARP inhibitors in head and neck cancer patients.
| Compound | Combination | Phase | State | NCT number |
|---|---|---|---|---|
| Olaparib | / | 1 | Not yet recruiting | NCT02686008 |
| RT | 1 | Recruiting | NCT01460888 | |
| RT | 1 | Recruiting | NCT02229656 | |
| RT + Cisplatin | 1 | Recruiting | NCT02308072 | |
| RT+ Cisplatin | 1 | Withdrawn | NCT01491139 | |
| RT+ Cisplatin | 1 | Recruiting | NCT01562210 | |
| Cisplatin | 2 | Recruiting | NCT02882308 | |
| RT + Cetuximab | 1 | Recruiting | NCT01758731 | |
| Veliparib | Chemotherapy | 1/2 | Suspended | NCT01711541 |
| Talazoparib | / | 1 | Not yet recruiting | NCT02567396 |
RT: Radiotherapy, NCT: Number clinicaltrials.gov identifier.